Abstract C020: First-in-human phase 1/1b trial of the first-in-class bi-steric mTORC1-selective inhibitor RMC-5552 in patients with advanced solid tumorsAlison M. Schram, Howard A. Burris, Michael L. Cheng et al.|Molecular Cancer Therapeutics|2023Cited by 8
The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 TrialAlison M. Schram, Justin Meyerowitz, Abdul Rafeh Naqash et al.|Clinical Cancer Research|2025Cited by 7
Abstract LB054: Confirmation of target inhibition and anti-tumor activity of the SHP2 inhibitor RMC-4630 via longitudinal analysis of ctDNA in a phase 1 clinical studyJosie Hayes, Eric B. Haura, Marianna Koczywas et al.|Cancer Research|2021Cited by 4
Abstract LB050: Modulation of innate and adaptive immunity in blood and tumor of patients receiving the SHP2 inhibitor RMC-4630Ariel Yung-Chia Chen, Pasi A. Jänne, Eric B. Haura et al.|Cancer Research|2021Cited by 3